Status:
COMPLETED
Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection
Lead Sponsor:
Wolfson Medical Center
Conditions:
Intravitreal Injection
Pain
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Intravitreal injections (IVI) are the mainstay of treatment modality in many ophthalmologic diseases including neovascular age-related macular degeneration (AMD), diabetic retinopathy and retinal vasc...
Eligibility Criteria
Inclusion
- Participants over the age of 18 years, receiving Bevacizumab IVI who are capable of signing a written informed consent form obtained under the Declaration of Helsinki.
Exclusion
- No consent to participate in the study.
- Incapability of signing a written informed consent form.
Key Trial Info
Start Date :
July 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 27 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04827836
Start Date
July 11 2021
End Date
December 27 2021
Last Update
December 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wolfson Medical Center
Holon, Central District, Israel, 5822012